PMID- 12904149
OWN - NLM
STAT- MEDLINE
DCOM- 20030826
LR  - 20220408
IS  - 1474-0338 (Print)
IS  - 1474-0338 (Linking)
VI  - 1
IP  - 2
DP  - 2002 Jul
TI  - IVIG in autoimmunity and cancer--efficacy versus safety.
PG  - 153-8
AB  - Intravenous immunoglobulin (IVIG) is an accepted treatment for certain 
      immunodeficiency states, but also for some autoimmune diseases. In other 
      autoimmune conditions (i.e., systemic lupus erythematosus), it is still empirical 
      although very efficacious. Based mainly on animal studies, IVIG has been shown to 
      exert different antitumour mechanisms that result in metastases suppression. This 
      effective therapy is associated with frequent occurrence of either immediate, 
      delayed or late adverse effects, most of which are mild and transient. Efforts 
      are taken in order to minimise these adverse effects both by pharmaceutical 
      companies that attempt to decrease the risk of infectious agents transmission, 
      and by physicians who monitor closely patients and choose the appropriate mode of 
      administration of IVIG with respect to dose, duration of treatment and 
      preparations used. Overall, IVIG is used in severe medical conditions and it is 
      quite safe. Future research would help to further minimise its associated risks.
FAU - Sherer, Yaniv
AU  - Sherer Y
AD  - Department of Medicine "B", Center of Autoimmune Diseases, Sheba Medical Center, 
      Tel-Hashomer & Sackler Faculty of Medicine, Tel-Aviv University, Israel.
FAU - Levy, Yair
AU  - Levy Y
FAU - Shoenfeld, Yehuda
AU  - Shoenfeld Y
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - *Autoimmune Diseases/drug therapy/immunology
MH  - Clinical Trials as Topic
MH  - Humans
MH  - *Immunoglobulins, Intravenous/adverse effects/immunology/therapeutic use
MH  - *Neoplasms/drug therapy/immunology
MH  - Safety
MH  - Tumor Cells, Cultured/drug effects
RF  - 36
EDAT- 2003/08/09 05:00
MHDA- 2003/08/27 05:00
CRDT- 2003/08/09 05:00
PHST- 2003/08/09 05:00 [pubmed]
PHST- 2003/08/27 05:00 [medline]
PHST- 2003/08/09 05:00 [entrez]
AID - 10.1517/14740338.1.2.153 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2002 Jul;1(2):153-8. doi: 10.1517/14740338.1.2.153.